Zum Beitrag: „Testosteronmangel im Alter – was ist zu tun“

Jaschke et al. diskutieren die Problematik des Testosteronmangels im Alter und hinterfragen den Wert der Testosterontherapie unter dem Aspekt einer „Anti-Aging”-Maßnahme [1]. Dabei findet die positive Nutzen-Risiko-Bilanz bei Typ-2-Diabetes (T2 D) kaum Beachtung.

Publikationsverlauf

Artikel online veröffentlicht:
19. Mai 2021

• Literatur

• 1 Jaschke NP, Rachner TD, Hofbauer LC. Testosteronmangel im Alter – was ist zu tun?. Dtsch Med Wochenschr 2021; 146: 141-145
• 2 Li S, Zhao Y, Yang Y. et al. Metabolic effects of testosterone replacement therapy in patients with type 2 diabetes mellitus or metabolic syndrome: A meta-analysis. Int J Endocrinol 2020; 2020: 4732021
• 3 Yassin A, Haider A, Haider K. et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: 8-year data from a registry study. Diabetes Care 2019; 42: 1104-1111
• 4 Haider K, Haider A, Saad F. et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes Obes Metab 2020; 22: 2055-2068
• 5 Wittert G, Bracken K, Robledo KP. et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol 2021; 9: 32-45
• 6 American Diabetes Association. Summary of Revisions: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41 (Suppl. 01) S4-S6
• 7 Salonia A, Bettocchi C, Carvalho J. et al EAU Guidelines on Sexual and Reproductive Health (2020). Im Internet (Stand: 19.4.2021): https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2021.pdf
• 8 Corna G, Rastrelli G, Guaraldi F. et al. An update on heart disease risk associated with testosterone boosting medications. Exp Opin Drug Safety 2019; 18: 321-332